Target Group Inc.

Target Group Inc. cultivates, processes, and distributes curated cannabis products for the adult-use medical and recreational cannabis market in Canada. Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k-cup infused coffee and tea pods, infused cannabis beverages and edibles, infused topical products, and CBD wellness products. The company also offers Wisp, a single-use pre-measured pod and vaporizer system for consumers involved in vaporizing natural herbs, including cannabis. It has a collaboration agreement with cGreen, Inc for manufacturing and distributing the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean; and distribution, collaboration, and licensing agreement with Serious Seeds B.V. The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. The company was incorporated in 2013 and is based in Hamilton, Canada.

Target Group Inc. trades as CBDY on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $3.88M of revenue and -$1.36M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Target Group Inc. can be compared against peers such as Allied Corp., Bionoid Pharma, Inc., Body and Mind Inc., CannaPharmaRX, Inc., Anything Technologies Media, Inc., Yooma Wellness Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $925,539, beta of 1.17, and return on equity of +16.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CBDY currently shows total debt of $1.03M and beta of 1.17. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 10-Q (2026-05-15 00:00:00), 10-K (2026-03-31 00:00:00), 10-Q (2025-11-07 00:00:00), 8-K (2025-08-18 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.targetgroupinc.ca

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.